Introduction {#j_jomb-2018-0022_s_001}
============

For more than 3 decades lung cancer has been the most common type of human malignancies, representing approximately 12--13% of all newly diagnosed cancer cases worldwide ([@j_jomb-2018-0022_ref_001], [@j_jomb-2018-0022_ref_002]). The estimated number of lung cancer related deaths has been constantly rising during this period ([@j_jomb-2018-0022_ref_002]). Although there have been improvements in lung cancer patient survival, it is still very poor with less than 18% 5-year survival rate ([@j_jomb-2018-0022_ref_003]). Therefore, scientists are persistently looking for novel and reliable molecular markers to improve diagnosis of lung cancer, optimize treatments and enable monitoring disease progression and response to therapy. Molecules that regulate cellular processes essential for maintaining malignant phenotype, such as c-Myc oncogene, stand out as promising candidates to serve as molecular markers. This nuclear phosphoprotein functions as transcriptional regulator of multiple genes and controls cell proliferation, induces apoptosis, and regulates stemness, senescence, metabolism and genome stability ([@j_jomb-2018-0022_ref_004]). Its expression is deregulated in number of human cancers including breast cancer, Burkitt's lymphoma, medulloblastoma, neuroblastoma and lung cancer ([@j_jomb-2018-0022_ref_005]). In most studies on non-small cell lung carcinoma (NSCLC), a predominant clinical form of lung cancer, c-Myc protein is overexpressed in 40--75% of cases ([@j_jomb-2018-0022_ref_006], [@j_jomb-2018-0022_ref_007], [@j_jomb-2018-0022_ref_008], [@j_jomb-2018-0022_ref_009]). Even though it is highly expressed in NSCLC, it does not associate with histopathological parameters and its prognostic value for this type of lung cancer is not clear ([@j_jomb-2018-0022_ref_007], [@j_jomb-2018-0022_ref_009], [@j_jomb-2018-0022_ref_010]). These data implicate that c-Myc is important for NSCLC pathogenesis but not sufficient to individually drive this process. Accordingly, we evaluated expression of *MYC* gene in 30 NSCLC patients' samples and analyzed its association with histopathological parameters and patients survival. Our main focus was to investigate the possible association of *MYC* expression with alterations in the genes previously identified to be related with NSCLC pathogenesis, *PHACTR3* and *E2F4* ([@j_jomb-2018-0022_ref_011]). The aim was to determine their mutual importance for NSCLC pathogenesis and potential to serve as molecular markers of this disease. Association analyses of *MYC* overexpression and aforementioned gene alterations were performed on whole set of patients' samples and samples stratified according to histopathological parameters. To evaluate their joint prognostic signifcance we analyzed their effects on patients' survival.

Materials and Methods {#j_jomb-2018-0022_s_002}
=====================

Tissue samples {#j_jomb-2018-0022_s_002_s_001}
--------------

We analyzed paired tumor samples and adjacent normal lung tissue from 30 patients with NSCLC who underwent surgery at the Clinic for Thoracic Surgery (Belgrade, Serbia). The specimens were frozen in liquid nitrogen, where they were kept until DNA and RNA extraction. The samples were collected and used after obtaining patients' informed consents and approval from the Ethics Committee, in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Diagnosis of NSCLC and its classification according to histological subtype, grade stage, and lymph node invasion were established by histological analyses of the surgical specimens. Distribution of all specimens by relevant histopathological parameters was presented previously ([@j_jomb-2018-0022_ref_011]). Overall, 9 adenocarcinomas and 21 squamous cell carcinomas were included in the study. 26 NSCLC samples were well to moderately differentiated (grade 1/2), while 4 were poorly differentiated (grade 3). 16 samples were in early pathological stages (stages I/II), and 14 cases were in late stage (stage III). Lymph node invasion was observed in 25 samples. Neither pre-surgical chemotherapy nor radiotherapy had been administered.

RNA extraction and Reverse Transcription {#j_jomb-2018-0022_s_002_s_002}
----------------------------------------

Total RNA was isolated from tumor and corresponding normal tissues samples of all 30 NSCLC patients. The isolation was carried out using Trizol® reagent (Invitrogen Life Technologies, USA) according to the manufacturer's instructions. RNA was quantified by spectrophotometry and quality was verified by agarose gel electrophoresis. Subsequently, reverse transcription reactions were performed using 2 mg of total RNA, with a High-capacity cDNA reverse transcription kit (Applied Biosystems), following the manufacturer's protocol.

Quantitative real-time PCR {#j_jomb-2018-0022_s_002_s_003}
--------------------------

Quantitative real time PCR (qRT-PCR) was performed to evaluate the mRNA expression level of *MYC* gene. PCR reactions with 100 ng of cDNA were performed using pair of primers specific for *MYC* transcripts ([@j_jomb-2018-0022_ref_012]). For each sample *ACTB* was used as a reference gene for the normalization of target gene expression ([@j_jomb-2018-0022_ref_013]). The primer sequences were as follows: 5'-CAA GAG GCG AAC ACA CAA CGT CT-3' (sense) and 5'-AAC TGT TCT CGT CGT TTC CGC AA-3' (antisense) for *MYC*, and 5 -TGG ACA TCC GCAAAG ACC TGT AC-3 (sense) and 5-TCA GGA GGA GCA ATG ATC TTG A-3 (antisense) for the *ACTB*. PCR reactions were performed using a Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, USA) on a QuantStudio 3 Real-Time PCR system (Thermo Fisher Scientific, USA) according to the manufacturer's recommendations. Each sample was tested in triplicate and relative gene expression levels were analyzed by the 2--ΔΔCt method ([@j_jomb-2018-0022_ref_014]).

Identification of NSCLC associated genes {#j_jomb-2018-0022_s_002_s_004}
----------------------------------------

In our preceding study we identified several genes not previously related to NSCLC pathogenesis ([@j_jomb-2018-0022_ref_011]). Overall procedure of identifying those genes included: DNA isolation, generation and comparison of AP-PCR profiles of paired normal and tumor DNA samples, selection of DNA bands with altered mobility in tumor versus matching normal samples and their further characterization through the reamplification, cloning and sequencing.

DNA extraction {#j_jomb-2018-0022_s_002_s_005}
--------------

DNA was extracted using the phenol/chloroform/isoamyl alcohol method ([@j_jomb-2018-0022_ref_015]). The quality of the DNA was verified by electrophoresis on 0.8% agarose gel and staining with ethidium bromide. The DNA concentration was established spectrophotometrically.

AP-PCR DNA fingerprinting {#j_jomb-2018-0022_s_002_s_006}
-------------------------

AP-PCR (Arbitrarily Primed Polymerase Chain Reaction) was used to generate DNA fingerprint profiles of paired DNA samples, normal and tumor, of the same patient ([@j_jomb-2018-0022_ref_016]). In short, six different, randomly chosen, primers were used to amplify DNA, initially under low-stringency conditions and then at high-stringency conditions, to generate informative fingerprints of moderate complexity that could distinguish tumor from normal tissue. The reactions were performed in a GeneAmp® PCR System 9700 (Applied Biosystems, Foster City, CA, USA) using PCR reaction kits supplied by Fermentas Life Sciences (Lithuania). Each reaction consisted of an initial denaturation step (95 °C for 5 min), 4 cycles at low-stringency conditions (specific for each primer), 35 cycles at high-stringency conditions (specific for each primer), and a final extension (72 °C for 7 min). Five out of six tested primers (p53 A, MDR A, E5A p53, GAPDH A, and GAPDH S) produced informative sequence alterations differentiating normal from tumor tissue. Primer sequences, AP-PCR amplification profiles and reaction conditions are described in our previous publications ([@j_jomb-2018-0022_ref_016], [@j_jomb-2018-0022_ref_011]) and summarized in *[Table I](#j_jomb-2018-0022_tab_001){ref-type="table"}*. The AP-PCR products were separated on 6-8% non-denaturing polyacrylamide gels and visualized by silver staining.

###### 

AP-PCR primer sequences, amplification profiles and reaction conditions.

  Primers   Sequences                               Amplification profiles          Reaction conditions             
  --------- --------------------------------------- ------------------------------- ------------------------------- -------------------------------------------------------------------------------
  p53A      5'-TTG GGC AGT GCT CGC TTA GT-3'        95 °C 30"; 40 °C 2'; 72 °C 1'   95 °C 30"; 60 °C 2'; 72 °C 1'   0.2 mmol/L each dNTP 3.5 mmol/L MgCl~2~ 5 μmol/L primer 1U Taq DNA Polymerase
  MDR A     5'-GTT CAA ACT TCT GCT CCT GA-3'        95 °C 30"; 40 °C 2'; 72 °C 1'   95 °C 30"; 58 °C 2'; 72 °C 1'   0.4 mmol/L each dNTP 2.5 mmol/L MgCl~2~ 5 μmol/L primer 1U Taq DNA Polymerase
  E5A p53   5'-CAG CCC TGT CGT CTC TCC AG-3'        95 °C 30"; 40 °C 2'; 72 °C 1'   95 °C 30"; 55 °C 2'; 72 °C 1'   0.6 mmol/L each dNTP 3.5 mmol/L MgCl~2~ 3 μmol/L primer 1U Taq DNA Polymerase
  GAPDH A   5'-AGC CTT CTC CAT GGT GGT GAA GAC-3'   95 °C 30"; 50 °C 2'; 72 °C 1'   95 °C 30"; 72 °C 2'; 72 °C 1'   0.2 mmol/L each dNTP 2.5 mmol/L MgCl~2~ 3 μmol/L primer 1U Taq DNA Polymerase
  GAPDH S   5'-CGG AGT CAA CGG ATT TGG TCG TAT-3'   95 °C 30"; 50 °C 2'; 72 °C 1'   95 °C 30"; 70 °C 2'; 72 °C 1'   0.4 mmol/L each dNTP 2.5 mmol/L MgCl~2~ 5 μmol/L primer 1U Taq DNA polymerase

Isolation, cloning and sequencing of altered bands {#j_jomb-2018-0022_s_002_s_007}
--------------------------------------------------

Some of the DNA bands with altered mobility, in tumor compared to normal samples, were selected for further characterization. Briefly, PCR amplicons of chosen bands were scrapped from silver stained gels with a hypodermic 22-gauge needle previously soaked in the PCR master mix solution. The needle was dipped in the PCR master mix for 2 min and then discarded. Further reamplification of the PCR products was performed with the same primers used for AP-PCR reactions at high-stringency conditions specific for each particular primer. The obtained products were cloned and sequenced as described ([@j_jomb-2018-0022_ref_011]). In short, the reamplified material was administrated on 1.5% agarose gels, than purified using DNA Extraction Kit (Fermentas Life Sciences, Lithuania) and cloned with GeneJetTM PCR Cloning Kit (Fermentas Life Sciences, Lithuania) according to manufacturers' instructions. After cloning procedure, plasmids were purified using GeneJetTM Plasmid Miniprep Kit (Fermentas Life Sciences, Lithuania). Further, sequencing was performed in both directions on several clones for each selected DNA band on an ABI Prism 3130 Genetic Analyzer automated sequencer (Applied Biosystems, Foster City, CA, USA) using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). The obtained sequences were analyzed using BLAST software in the NCBI GenBank and EBI (Sanger Institute) database to identify selected alterations.

Statistical analysis {#j_jomb-2018-0022_s_002_s_008}
--------------------

Significant differences between the data sets were determined by GraphPad Prism 6 software (La Jolla, CA USA) and statistical package R (version 3.1.3 (2015-03-09) Copyright (C) 2015 The R Foundation for Statistical Computing). Paired t-test was used to assess statistical differences in expression level of *MYC* gene between paired tumor and normal sample of each patient. On the other hand, difference in *MYC* relative expression level between total tumor and normal samples was evaluated using unpaired t-test. Fisher exact test was used to examine the relationship between histopathological parameters (histological subtype, grade stage, and lymph node invasion) and *MYC* overexpression. The same statistical analysis was used to study the possible associations between frequencies of *MYC* overexpression and alterations in *PHACTR3* and *E2F4*. Survival analyses were performed by Kaplan & Meier product-limit method. The log rank test was used to evaluate the significance of the difference between pairs of survival probabilities. Overall survival rate was calculated from day one after surgery to the last follow-up examination or death of the patient. The total follow up period was 117 months. Statistical differences were considered significant when *p* value was \< 0.05.

Results {#j_jomb-2018-0022_s_003}
=======

MYC gene expression analysis {#j_jomb-2018-0022_s_003_s_001}
----------------------------

Alterations in *MYC* gene expression between tumor and matching normal samples were analyzed by qRT-PCR. *MYC* gene expression was significantly higher in NSCLC samples (*p* = 0.018) compared with normal lung samples (*[Figure 1](#j_jomb-2018-0022_fig_001){ref-type="fig"}*). Specifically, *MYC* gene was overexpressed in 11 out of 30 tumor samples (37%).

![*MYC* gene expression. Box plot analysis of *MYC* expression level in primary tumor (T) and normal (N) samples. Results are presented as log2 of *MYC* gene expression relative to *ACTB* gene level. ^∗^ indicates *p*\<0.05 as significant gene overexpression in tumor samples compared to normal samples.](jomb-38-188-g001){#j_jomb-2018-0022_fig_001}

Increased MYC gene expression in relation to histopathological parameters {#j_jomb-2018-0022_s_003_s_002}
-------------------------------------------------------------------------

Significance of *MYC* overexpression was initially evaluated in relation to major histopathological parameters: NSCLC subtype, histological grade, stage and lymph node invasion (*[Table II](#j_jomb-2018-0022_tab_002){ref-type="table"}*). Statistical analyses revealed that *MYC* overexpression was significantly associated with histological subtype (*p*=0.01). In adenocarcinoma increased *MYC* expression was completely absent (0/9), while in squamous cell carcinoma *MYC* overexpression was more frequently present (11/21, 52.4%).

###### 

Association between *MYC* overexpression and histopathological parameters.

  Parameter                                                                Total NP[^b^](#j_jomb-2018-0022_fn_001){ref-type="table-fn"}   *MYC* overexpression               
  ------------------------------------------------------------------------ -------------------------------------------------------------- ---------------------- ----------- --------------------------------------------------------------
  Total                                                                    30                                                             11                     19          
  NSCLC subtype                                                                                                                                                              
  Adenocarcinoma                                                           9                                                              0 (0.0)                9 (100.0)   **0.01**[^c^](#j_jomb-2018-0022_fn_002){ref-type="table-fn"}
  Squamous cell carcinoma                                                  21                                                             11 (52.4)              10 (47.6)   
  Histological grade[^a^](#j_jomb-2018-0022_fn_003){ref-type="table-fn"}                                                                                                     
  g^1/2^                                                                   26                                                             11 (42.3)              15 (57.7)   0.36
  g^3^                                                                     4                                                              0 (0.0)                4 (100.0)   
  Stage                                                                                                                                                                      
  I/II                                                                     16                                                             6 (37.5)               10 (62.5)   1
  III                                                                      14                                                             5 (35.7)               9 (64.3)    
  Lymph node invasion                                                                                                                                                        
  Positive                                                                 25                                                             9 (36.0)               16 (64.0)   1
  Negative                                                                 5                                                              2 (40.0)               3 (60.0)    

NP number of patients per group;

bold indicates statistically significant value, *p*\<0.05.

g^1/2^, well to moderately differentiated; g^3^, poorly differentiated;

Increased MYC gene expression in relation to gene alterations {#j_jomb-2018-0022_s_003_s_003}
-------------------------------------------------------------

We further examined *MYC* expression in relation to the presence of alterations in *PHACTR3* and *E2F4*. In previous study ([@j_jomb-2018-0022_ref_011]), mutations in these two genes were identified according to sequence data and BLAST search results. Specifically, multiple nucleotide substitutions were detected in *PHACTR3* and *E2F4*.

Association between MYC overexpression and altered PHACTR3 gene {#j_jomb-2018-0022_s_003_s_004}
---------------------------------------------------------------

Patients with altered *PHACTR3* gene had more frequently increased *MYC* gene expression ([Table III](#j_jomb-2018-0022_tab_003){ref-type="table"}; *p*=0.015). Among six patients with altered *PHACTR3* gene, 5 (83.3%) had increased *MYC* mRNA level, while in 1 patient (16.7%) *MYC* was not overexpressed. Similar association was present in subgroup of patients with squamous cell carcinoma (*[Table III](#j_jomb-2018-0022_tab_003){ref-type="table"}*; *p*=0.035). In this group all patients with *PHACTR3* alterations had overexpressed *MYC*.

###### 

Association of overexpressed *MYC* oncogene with altered *PHACTR3* and *E2F4* genes.

                         *MYC* overexpression                                            Squamous cell carcinoma                          
  ---------------------- --------------------------------------------------------------- ------------------------- ---------- ----------- ---------
  *PHACTR3* alteration   Yes                                                             5 (83.3)                  1 (16.7)   5 (100.0)   0 (0.0)
  No                     6 (25.0)                                                        18 (75.0)                 6 (37.5)   10 (62.5)   
  *p* value              **0.015**[^b^](#j_jomb-2018-0022_fn_006){ref-type="table-fn"}   **0.035**                                        
  *E2F4* alteration      Yes                                                             5 (83.3)                  1 (16.7)   5 (100.0)   0 (0.0)
  No                     6 (25.0)                                                        18 (75.0)                 6 (37.5)   10 (62.5)   
  *p* value              **0.015**[^b^](#j_jomb-2018-0022_fn_006){ref-type="table-fn"}   **0.035**                                        

NP number of patients per group;

bold indicates statistically significant values, *p*\<0.05.

Association between MYC overexpression and altered E2F4 gene {#j_jomb-2018-0022_s_003_s_005}
------------------------------------------------------------

*MYC* overexpression in the presence of *E2F4* gene alterations showed the same pattern of conjunction as with the incidence of altered *PHACTR3* gene (*[Table III](#j_jomb-2018-0022_tab_003){ref-type="table"}*). Namely, 83.3% of patients with abnormal *E2F4* had overexpressed *MYC* compared to 16.7% of patients that did not show overexpression of this oncogene (*p*=0.015). In squamous cell carcinoma subtype altered *E2F4* exclusively coincided with *MYC* overexpression (100%) while unchanged *E2F4* was predominantly associated with non-overexpressed *MYC* (62.5% versus 37.5%; *p*=0.035).

Effects of gene alterations and MYC overexpression on survival rate {#j_jomb-2018-0022_s_003_s_006}
-------------------------------------------------------------------

Kaplan-Meier survival curves were analyzed to evaluate the effect of *MYC* gene overexpression in the presence of aforementioned gene alterations on NSCLC patients' survival. When individually examined, *MYC* overexpression did not significantly affect the survival rate (*[Figure 2A](#j_jomb-2018-0022_fig_002){ref-type="fig"}*; *p*=0.646). However, when considered in combination with altered *PHACTR3* and *E2F4*, *MYC* overexpression showed tendency towards shorter survival although did not reach statistical significance. The median survival time was 1 month for patients with overexpressed *MYC* and altered *PHACTR3* or *E2F4* compared to 7.5 months for those with overexpressed *MYC* only (*[Figure 2B](#j_jomb-2018-0022_fig_002){ref-type="fig"} and [C](#j_jomb-2018-0022_fig_002){ref-type="fig"}*; *p*=0.138).

![Kaplan--Meier overall survival analyses. No difference in survival was observed between patients with overexpressed (*MYC*+) and non-overexpressed *MYC* gene (*MYC*-) (A). Patients with overexpressed *MYC* and mutated *E2F4* (*MYC*+/ *E2F4*+) (B) or *PHACTR3* (*MYC*+/ *PHACTR3*+) (C) showed trend of decreased survival compared to those with overexpressed *MYC* only (*MYC*+/ *E2F4*-, *MYC*+/ *PHACTR3*-).](jomb-38-188-g002){#j_jomb-2018-0022_fig_002}

Discussion {#j_jomb-2018-0022_s_004}
==========

C-Myc is one of the most important cellular oncogenes necessary for malignant transformation ([@j_jomb-2018-0022_ref_017]). Deregulation of its expression is critical for the pathogenesis of various cancer types, including lung cancer ([@j_jomb-2018-0022_ref_005]). C-Myc protein is overexpressed in 40--75% of NSCLC patients ([@j_jomb-2018-0022_ref_006], [@j_jomb-2018-0022_ref_007], [@j_jomb-2018-0022_ref_008], [@j_jomb-2018-0022_ref_009]). However, data obtained by RT-PCR are not consistent. Wu et al. have reported only 18% NSCLC cases with *MYC* overexpression ([@j_jomb-2018-0022_ref_018]), while Hsu and colleagues have found overexpressed *MYC* in 91% of NSCLC patients' samples ([@j_jomb-2018-0022_ref_019]). In our study, we evaluated *MYC* gene expression by qRT-PCR analysis in 30 NSCLC patients' samples and observed its overexpression in 37% of cases. This result corresponds to most studies on c-Myc protein expression ([@j_jomb-2018-0022_ref_007], [@j_jomb-2018-0022_ref_020]). Moreover, we have observed for the first time that *MYC* overexpression is a significant characteristic of squamous cell carcinoma subtype rather than adenocarcinoma. C-Myc overexpression was previously shown to be more frequently present in squamous cell carcinoma but without statistical significance ([@j_jomb-2018-0022_ref_009]), while Xu et al. ([@j_jomb-2018-0022_ref_008]) reported it to be significant characteristic of adenocarcinoma.

Major focus of this study was to analyze *MYC* gene overexpression in relation to alterations in genes associated with NSCLC pathogenesis ([@j_jomb-2018-0022_ref_011]). Tested gene alterations, *PHACTR3* and *E2F4* were shown to be associated with *MYC* overexpression. Moreover, these alterations significantly coincide with *MYC* overexpression in squamous cell carcinoma. PHACTR3 (Phosphatase and actin regulator 3/ scaffold-associated PP1 inhibiting protein), also known as scapinin, is a protein phosphatase 1-binding protein associated with nuclear non-chromatin structures (the nuclear matrix or nucleoskeleton) ([@j_jomb-2018-0022_ref_021]). It directly interacts with actin and regulates actin cytoskeleton structures influencing cell spreading and motility ([@j_jomb-2018-0022_ref_022]). At the same time, nuclear F-actin activates transcription of c-Myc through Wnt/β-catenin signaling ([@j_jomb-2018-0022_ref_023]). We speculate that actin could be one of potential interconnections between *PHACTR3* alterations and *MYC* overexpression. In our previous study *PHACTR3* was shown to be altered in 6 out of 30 patients, mostly with squamous cell carcinoma ([@j_jomb-2018-0022_ref_011]). Recently, significance of *PHACTR3* as parameter for non-invasive lung cancer diagnosis was evaluated along with other diagnostic and risk biomarkers ([@j_jomb-2018-0022_ref_024]).

Considering interrelationship between *MYC* overexpression and mutational status of *E2F4* the observed positive association is not surprising. E2F4 is a part of complex involved in repression of *MYC* transcription in response to different signals ([@j_jomb-2018-0022_ref_025]). This transcriptional regulator was shown to be necessary for normal development of lung tissue ([@j_jomb-2018-0022_ref_026]). However, its importance and role in pathogenesis of NSCLC was examined only in our earlier publication ([@j_jomb-2018-0022_ref_011]). In that study, altered *E2F4* was detected in 20% of patients, predominantly with squamous cell carcinoma.

The influence of c-Myc overexpression on NSCLC patient survival is inconclusive. Some authors showed c-Myc association with shorter survival ([@j_jomb-2018-0022_ref_009]), while others reported no effects on NSCLC prognosis ([@j_jomb-2018-0022_ref_007]). We observed no significant difference in life span between NSCLC patients with overexpressed and non-overexpressed *MYC* gene. However, the presence of altered *PHACTR3* or *E2F4* along with overexpressed *MYC* contributed to shorter survival but without prognostic significance. Considering our previous results this joint effect of *MYC* and altered genes could be mainly attributed to the significant negative effects of altered *PHACTR3* and *E2F4* genes on NSCLC patients' survival ([@j_jomb-2018-0022_ref_011]).

Overall this study implicates frequent presence of overexpressed *MYC* gene in NSCLC patients and its applicative potential as molecular marker of squamous cell carcinoma. Additionally, the results point out the relevance of overexpressed *MYC* in association with altered *PHACTR3* and *E2F4* genes as joint molecular markers of NSCLC and its specific subtypes. Most importantly, we identified positive associations between *MYC* overexpression and aforementioned gene alterations not previously considered in NSCLC nor other cancer types, therefore opening a novel research perspective in studying c-Myc role in carcinogenesis. In this context, functional interconnection of *MYC* and altered genes will be of particular interest in our further studies.
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NSCLC

:   non-small cell lung carcinoma

qRT-PCR

:   quantitative real time polymerase chain reaction

AP-PCR

:   arbitrarily primed polymerase chain reaction

ACTB

:   beta-actin

PHACTR3

:   phosphatase and actin regulator 3/ scaffold-associated PP1 inhibiting protein.
